Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC
Low pre-treatment expression of immunoproteasome subunits LMP2, PSME1, and PSME2 predicts favorable pathologic response to NACI in resectable NSCLC. High baseline LMP2 expression, along with MPR achievement, independently associates with improved survival. These findings nominate LMP2/PSME1/PSME2 as novel, IHC-detectable biomarkers for stratifying NACI response and prognosis, highlighting the critical role of antigen processing machinery in modulating treatment efficacy. Validation in larger prospective cohorts is warranted.
Authors
- Rongxia Xie
- Kefeng Zhai (ORCID: https://orcid.org/0000-0002-5198-4332)
- Miaoqing Zhao (ORCID: https://orcid.org/0000-0001-9683-6483)
- Jinming Yu (ORCID: https://orcid.org/0000-0002-8537-839X)
Institutions
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1654573
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- National Science and Technology Major Project